Call for Expressions of Interest: ESMO Biomolecular Technologies Survey

In 2023, ESMO published the results of the “ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe”in Annals of Oncology (Bayle et al.). ESMO are now looking to expand the survey globally to provide a broader perspective and assessment of the availability and accessibility of biomolecular technologies; and running a focused study on liquid biopsy and the availability and implementation challenges. 

ESMO have invited MOGA to nominate 3 individuals to provide data for Australia and professional support for this study: 2 medical oncologists and 1 pathologist (this request referred to RCPA but can proceed with a MOGA member with relevant training).  

MOGA representatives will be required to participate in a comprehensive survey (approx. 30 minutes to complete) designed to assess the availability, accessibility, and out-of-pocket costs associated with biomolecular technologies within Australia. ESMO will then undertake a thorough analysis of the data and subsequently engage the reviewers to validate the accuracy and integrity of the collected data (peer review process). 

The survey will be based on the previous one conducted in Europe, updated with the new NGS recommendations published by the ESMO and will include a dedicated study on liquid biopsy - given the specificity of this innovative approach. 

If you are interested, please submit a brief EOI (no more than 400 characters) and a brief bio via email to moga@moga.org.au by COB Tuesday 10 June 2025. Please reach out if you have any questions about the role.